Genelux Corp (GNLX): R&D Expense
$19.85M
Year ended 2025-12-31
$22.68M
Trailing 12 months to 2026-06-30
+29.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.85M | +4.5% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $19.00M | +48.8% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $12.77M | +40.6% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $9.08M | n/a | 2024-03-29, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Genelux Corp (GNLX) | 2025-12-31 | $19.85M | +4.5% |
| Aspire Biopharma Holdings, Inc. (ASBP) | 2025-12-31 | $923.9K | +540.0% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.36M | +276.5% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $1.14M | -90.3% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $3.19M | -70.7% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $6.03M | -10.2% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $340.0K | +22.3% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
Compare GNLX, ASBP, TCRT, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗